eganelisib usan codenamed experimental drug investigated possible treatment cancer highly selective phosphoinositide inhibitor thus works inhibiting enzyme disrupting signaling pathway plays important roles development eganelisib developed infinity pharmaceuticals early clinical trial results published september september granted fast track designation united states food drug administration fda treatment inoperable locally advanced metastatic triplenegative breast cancer combined checkpoint inhibitor october five phase iii clinical trials ongoing united states one antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikieganelisib